Related Experiment Video

Updated: Jul 8, 2026

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

Surgical management of hypertrophic cardiomyopathy in 2007: what is new?

Morgan L Brown1, Hartzell V Schaff

  • 1Division of Cardiovascular Surgery, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

World Journal of Surgery
|January 19, 2008
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) presents variably. Recent advances improve diagnosis and genetic understanding, guiding personalized pharmacologic therapy, alcohol septal ablation, or surgical myectomy for better patient outcomes.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Diagnostics

Background:

  • Hypertrophic cardiomyopathy (HCM) exhibits diverse clinical presentations and variable penetrance.
  • While many patients experience a benign course, some develop symptomatic left ventricular outflow tract obstruction.
  • Understanding the genetic underpinnings of HCM is rapidly evolving.

Purpose of the Study:

  • To summarize recent advancements in the diagnosis of hypertrophic cardiomyopathy.
  • To review current and emerging therapeutic strategies for HCM.
  • To provide evidence-based guidance for patient management decisions.

Main Methods:

  • Review of recent literature on hypertrophic cardiomyopathy diagnosis and treatment.
  • Analysis of echocardiographic findings in HCM assessment.
  • Evaluation of genetic studies related to HCM etiology.
  • Comparison of pharmacologic therapy, alcohol septal ablation, and surgical septal myectomy.

Main Results:

  • Echocardiography remains the gold standard for diagnosing HCM and assessing obstruction.
  • Significant progress has been made in understanding the genetic basis of HCM.
  • Pharmacologic therapy is the primary treatment, with interventional procedures reserved for specific cases.
  • Patient-specific risk-benefit assessments are crucial for procedural decisions.

Conclusions:

  • Recent developments enhance the diagnosis and genetic understanding of HCM.
  • Personalized therapeutic approaches, including pharmacologic and interventional options, are key.
  • Informed patient decision-making, considering procedural risks and benefits, is paramount for managing HCM.

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...